Use of the lidocaine patch 5% in the treatment of neuropathic pain

Journal of Neuropathic Pain and Symptom Palliation

Volumn 2, Issue 4, 2008, Pages 3-13

  Nalamachu, Srinivas ^a   Gould, Errol M ^b   Gammaitoni, Arnold R ^b  

^a Mid America Physiatrists   (United States)

^b ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Lidocaine patch 5 ; Neuropathic pain; Nociceptors; Peripheral neuropathy; Sodium channels; Topical analgesic

Indexed keywords

EID: 68949115758     PISSN: 15437698     EISSN: 15437701     Source Type: Journal    
DOI: 10.1300/J426v02n04_02     Document Type: Article

References (92)

1. Argoff CE. Conclusions: chronic pain studies of lido- caine patch 5% using the Neuropathic Pain Scale. Curr Med Res Opin. 2004a;20(suppl 2):S29-S31.
2. Argoff CE. New analgesics for neuropathic pain: the lidocaine patch. Clin J Pain. 2000;16:S62-S66.
3. Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin. 2004b;20(suppl 2):S21-S28.
4. Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage. 2004c;28:396-411.
5. Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosen I. Prevalence of carpal tunnel syndrome in a general population. JAMA. 1999;282:153-158.
6. Balser JR, Nuss HB, Orias DW, et al. Local anesthetics as effectors of allosteric gating. Lidocaine effects on inactivation-deficient rat skeletal muscle Na channels. J Clin Invest. 1996;98:2874-2886.
7. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella- Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61:914-918.
8. Baron R, Wasner G. Prevention and treatment of post- herpetic neuralgia. Lancet. 2006;367:186-188.
9. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Ann Rev Neurosci. 1984;7:309-338.
10. Berman SM, Justis JC, Ho MI, Ing M, Eldridge D,Gammaitoni A. Lidocaine patch 5%(Lidoderm®) improves common pain qualities reported by patients with HIV-associated painful peripheral neuropathy: an open-label pilot study using the Neuropathic Pain Scale. Presented at the 10th World Congress of Pain;2002.
11. Besson JM, Chaouch A. Peripheral and spinal mechanisms of nociception. Physiology Reviews. 1987;67:67-186.
12. Black JA, Cummins TR, Plumpton C, et al. Upregu- lation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. J Neuro- physiol. 1999;82:2776-2785.
13. Burch F, Codding C, Patel N, Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage. 2004;12:253-255.
14. Byers MR, Bonica JJ. Peripheral pain mechanisms and nociceptor plasticity. In: Loeser JD, ed. Bonica's Management of Pain. 3rd ed. Philadelphia: Lippin- cott Williams & Wilkins; 2001:26-72.
15. Carpenter MB. Core Text of Neuroanatomy. Baltimore,MD: Wiliams & Wilkins; 1978.
16. Cayley WE, Jr. Antidepressants for the treatment of neuropathic pain. Am Fam Physician. 2006;73:1933-1934.
17. Chen Z, Ong BH, Kambouris NG, Marban E, Tomaselli GF, Balser JR. Lidocaine induces a slow inactivated state in rat skeletal muscle sodium channels. J Physiol. 2000;524 Pt 1:37-49.
18. Collins SD, Chessell IP. Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005;10:95-108.
19. Comer AM, Lamb HM. Lidocaine patch 5%. Drugs. 2000;59:245-249.
20. Dalpiaz AS, Dodds TA. Myofascial pain response to topical lidocaine patch therapy: case report. Journal of Pain & Palliative Care Pharmacotherapy. 2002;16:99-104.
21. Dalpiaz AS, Lordon SP, Lipman AG. Topical lidocaine patch therapy for myofascial pain. Journal of Pain & Palliative Care Pharmacotherapy. 2004;18:15-34.
22. Davis MDP. Lidocaine patch helpful in managing the chronic pain of leg ulceration. Journal of the American Academy Dermatology. 2003;49:964.
23. Davis MDP, Sandroni P. Lidocaine patch for pain of erythromelalgia. Arch Dermatol. 2002;138:17-19.
24. Davis MDP, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol. 2005;141:1320-1321.
25. Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain. 2000;16:205-208.
26. Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain. 2006;7:S3-S12.
27. Devor M, Govrin-Lippmann R, Angelides K. Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci. 1993;13:1976-1992.
28. Djouhri L, Koutsikou S, Fang X, McMullan S, Lawson SN. Spntaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. J Neurosci. 2006;26:1281-1292.
29. Dworkin R, Hart-Gouleau S, Galer B, Gammaitoni A, Domingos J. Effectiveness and impact on quality of life of the lidocaine patch 5% in painful diabetic neuropathy patients with or without allodynia [abstract]. J Pain. 2003a;42:35.
30. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003b;60:1524-1534.
31. Dyck PJ, Kratz KM, Litchy WJ, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population- based cohort: The Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824.
32. Endo Pharmaceuticals I. Lidoderm®(lidocaine patch5%). 2004.
33. Fields HL, Basbaum AI. Central nervous systemmecha- nisms of pain modulation. In: Wall PD, Melzack R, eds. Textbook of Pain. 3rd ed. New York: Churchill Livingstone; 1994:243-257.
34. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation.Neurobiol Dis. 1998;5:209-227.
35. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005;118:289-305.
36. Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis. 2004a;63:1372-1378. (Pubitemid 39433938)
37. Fraenkel L, Bogardus ST Jr, Concato J, Wittink DR. Treatment options in knee osteoarthritis: the patient's perspective. Arch Intern Med. 2004b;164:1299-1304. (Pubitemid 38828880)
38. Galer B, Kivitz A, Fairfax M, Sheldon E, Oleka N, Gammaitoni A. A randomized open-label study comparing the efficacy and safety of lidocaine patch 5% with celecoxib 200 mg in patients with pain from osteoarthritis of the knee [abstract]. J Pain. 2005a;6:S51.
39. Galer B, Oleka N, Gammaitoni A. Lidocaine patch 5% improves outcomes for low-back pain and osteo- arthritis patients receiving COX-2 selective or traditional NSAID therapy for pain relief [abstract]. JPain. 2005b;6:S50.
40. Galer BS. Topical medications. In: Loeser JD, ed. Bonica's Management of Pain. 3rd ed. 2001:1736-1741.
41. Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med. 2003;163:628.
42. GalerBS, Gammaitoni AR. Use of Topiceuticals(Topically Applied, Peripherally Acting Drugs) in the Treatment of Chronic Pain. Current Drug Therapy. In Press.
43. Galer BS, Gammaitoni AR, Oleka N, Jensen MP, Argoff CE. Use of the lidocaine patch 5% reduces intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin. 2004;20(suppl 2):S5-S12.
44. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain.1999;80:533-538.
45. Gammaitoni A, Galer B, Burch F. Effectiveness and safety of the lidocaine patch 5% as monotherapy in patients with pain from osteoarthritis of the knee [abstract]. J Pain. 2003;4:78.
46. Gammaitoni A, Oleka N, Galer B. Lidocaine patch 5% improves outcomes for post-herpetic neuralgia patients receiving COX-2/anti-inflammatory, opioid, or adjuvant analgesics [abstract]. J Pain. 2005;6:S49.
47. Gammaitoni AR, Alvarez NA, Galer BS. Pharma- cokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm. 2002;59:2215-2220.
48. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002;36:236-240.
49. Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results ofa pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin. 2004;20(suppl 2):s13-s19.
50. Gimbel J, Hale M, Linn R, Galer B, Kurkimills E,Gammaitoni A. Lidocaine patch 5% in patients with acute/subacute and chronic low back pain: impact on pain intensity, pain relief, and pain interference with quality of life [abstract]. J Pain. 2003;4:71.
51. Gimbel J, Linn R, Hale M, Nicholson B. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. Am J Ther. 2005;12:311-319.
52. Gold MS. Sodium channels and pain therapy. Curr Opin Anaesthesiol. 2000;13:565-572.
53. Guazzi MD, Campodonico J, Celeste F, et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clin Pharmacol Ther. 1998;63:79-86.
54. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781-786.
55. Herrmann DN, Barbano RL, Hart-Gouleau S, Pennella- Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med. 2005;6:379-384.
56. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. Journal of General Physiology. 1977;69:497-515.
57. Hughes RA. Peripheral neuropathy. BMJ. 2002;324: 466-469.
58. Jensen MP. Introduction: chronic pain studies of the lidocaine patch 5% using the neuropathic pain scale. Curr Med Res Opin. 2004;20(suppl 2):S1-S4.
59. Johnson AG, Seideman P, Day RO. Adverse drug interaction with nonsteroidal anti-inflammatory drugs(NSAIDs). Drug Saf. 1993a;8:99-127.
60. Johnson AG, Simons LA, Simons J, Friedlander Y, McCallumJ. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. J Clin Pharmacol. 1993b;35:455-459.
61. Kalso E. Sodium channel blockers in neuropathic pain.Curr Pharm Des. 2005;11:3005-3011.
62. Kanazi GE, Johnson RW, Dworkin RH. Treatment of postherpetic neuralgia: an update. Drugs. 2000;59:1113-1126.
63. Katz N, Davis MW, Dworkin R. Topical lidocaine patch produces a significant improvement in quality of life indicators in treated PHN patients: results of a multicenter open-label trial [abstract]. Pain Med.2001;2:342-1243
64. Koopmans PP, Thien T, Thomas CM, Van den Berg RJ, Gribnau FW. The effects of sulindac and indo- methacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension. Br J Clin Pharmacol.1986;21:417-423.
65. LaMotte C. Distribution of the tract of Lissauer and the dorsal root fibers in the primate spinal cord. J Comp Neurol. 1977;172:529-561.
66. Lilly. CYMBALTA®. August 22, 2006.
67. Lipman A, Dalpiaz A, Lordon S. Topical lidocaine patch therapy for myofascial pain [abstract]. J Pain.2002;3:46.
68. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106:151-158.
69. Millan MJ. The induction of pain: an integrative review.Prog Neurobiol. 1999;57:1-164.
70. Nalamachu S, Crockett RS, Gammaitoni AR, Gould EM. A comparison of the lidocaine patch 5% vs.naproxen 500 mg bid for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group study. Medscape General Medicine.2006;8:3.
71. Nalamachu S, Crockett RS, Mathur D. Lidocaine patch 5% for carpal tunnel syndrome: How it compares with injections: A pilot study. J Fam Pract. 2006b; 55:209-214.
72. Nicholson B, Galer BS, Oleka N, Gammaitoni AR. A randomized open-label study comparing the effficacy and safety of lidocaine patch 5% with celecoxib 200 mg in patients with chronic axial low-back pain [abstract]. Arthritis Rheum. 2005;52:S523-S524.
73. Nordin M, NystromB, Wallin U, Hagbarth KE. Ectopic sensory discharges and paresthesiae in patients with disorders of peripheral nerves, dorsal roots and dorsal columns. Pain. 1984;20:231-245.
74. Nystrom B, Hagbarth KE. Microelectrode recordings from transected nerves in amputees with phantom limb pain. Neurosci Lett. 1981;27:211-216.
75. Ochoa J, Torebjork HE, Culp WJ, Schady W. Abnormal spontaneous activity in single sensory nerve fibers in humans. Muscle and Nerve. 1982;5:S74-S77.
76. Papanicolaou GD, McCabe SJ, Firrell J. The prevalence and characteristics of nerve compression symptoms in the general population. Journal of Hand Surgery [Am]. 2001;26:460-466.
77. Pertin M, Ji RR, Berta T, et al. Upregulation of the voltage-gated sodium channel b2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons. J Neurosci. 2005;25:10970-10980.
78. Pfizer I. Neurontin®(gabapentin) Capsules. December,2005.
79. Pfizer I. LYRICA®(pregabalin). March, 2006.
80. RowbothamMC, Davies PS, VerkempinckC, GalerBS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia.Pain. 1996;65:39-44.
81. Sandtner W, Szendroedi J, Zarrabi T, et al. Lidocaine: a foot in the door of the inner vestibule prevents ultra-slow inactivation of a voltage-gated sodium channel. Mol Pharmacol. 2004;66:648-657.
82. Sawynok J. Topical and peripherally acting analgesics.Pharmacol Rev. 2003;55:1-20.
83. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-354.
84. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
85. Sluiter JK, Rest KM, Frings-Dresen MH. Criteria document for evaluating the work-relatedness of upper-extremity musculoskeletal disorders. Scand J Work Environ Health. 2001;27:1-102.
86. Terman GW, Bonica JJ. Spinal mechanisms and their modulation. In: Loeser JD, Butler SH, Chapman CR, Turk DC, eds. Bonica's Management of Pain. 3rd ed.Philadelphia: Lippincott, Williams, & Wilkins; 2006:73-152.
87. Wang SY, Mitchell J, Moczydlowski E, Wang GK. Block of inactivation-deficient Na+ channels by local anesthetics in stably transfected mammalian cells: evidence for drug binding along the activation pathway. Journal of General Physiology. 2004; 124:691-701.
88. Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: Topical lidocaine is effective in nociceptor-deprived skin. J Neurol.2005;252:686.
89. Waxman SG, Dib-Hajj S, Cummins TR, Black JA. Sodium channels and pain. Proc Natl Acad Sci USA.1999;96:7635-7639.
90. White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gaba- pentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med. 2003;4:321-330.
91. Willis WD. The Pain System: the Neural Basis ofNoci- ceptive Transmission in the Mammalian Nervous System. Basel: Karger; 1985.
92. Wong DG, Spence JD, Lamki L, Freeman D, McDonald JWD. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet. 1986;00:997-1001.